Argus downgraded Baxter from Buy to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2025 | Buy → Hold | Argus | |
| 8/4/2025 | $25.00 | Buy → Hold | Stifel |
| 8/1/2025 | $25.00 | Buy → Neutral | Goldman |
| 2/26/2025 | $42.00 | Buy | Goldman |
| 2/24/2025 | Hold → Buy | Argus | |
| 2/20/2025 | $39.00 | Overweight | Barclays |
| 7/15/2024 | $39.00 → $30.00 | Equal-Weight → Underweight | Morgan Stanley |
| 5/30/2024 | $36.00 | Neutral | Goldman |
Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2026 Annual Meeting) in a virtual format on Tuesday, May 5, 2026 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the 2026 Annual Meeting. Online access to the 2026 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2026 Annual Meeting in person. The virtual format provides a safe, convenient and cost-effective experience to all stockholders and employees, regardless of location. Anyone who would like to attend the virtual 2026 Annual Meeting is encouraged to access the meeting in advance of the designated star
Largest Single Investment from a Corporate Foundation Aims to Strengthen Healthcare Resilience by Advancing Therapy Animal Visits in U.S. Healthcare SettingsBELLEVUE, Wash. and DEERFIELD, Ill., March 25, 2026 /PRNewswire/ -- Pet Partners, the nation's leading organization dedicated to improving human health and well-being through therapy animal interactions, and the Baxter Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced a new partnership to expand access to therapy animal programs in healthcare settings across the country. The initiative will begin as a two-year pilot program in key regions, including Northern California, Up
Joel Grade to depart as Baxter CFO; Anita Zielinski named interim CFO Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the departure of executive vice president and chief financial officer (CFO) Joel Grade. Mr. Grade is leaving the company to prioritize family matters but will continue in an advisory capacity until April 30, 2026. Baxter has named Anita Zielinski as interim CFO, effective immediately, while the company conducts its search to fill the role. Ms. Zielinski joined Baxter in 2025 as senior vice president, chief accounting officer and controller, and will continue with these responsibilities in addition to serving as interim CFO. She joined Baxte
For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
DEFA14A - BAXTER INTERNATIONAL INC (0000010456) (Filer)
DEF 14A - BAXTER INTERNATIONAL INC (0000010456) (Filer)
8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
Argus downgraded Baxter from Buy to Hold
Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00
Goldman downgraded Baxter from Buy to Neutral and set a new price target of $25.00
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as
Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca
Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis1,2 Fourth-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($2.01); adjusted diluted EPS from continuing operations of $0.44 Company advances ongoing board of directors refreshment Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. "While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise," said And
Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its fourth-quarter 2025 financial results on Thursday, February 12, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I81994118 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and eve
Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the consideration payable in connection with the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The table below sets forth the Total Consideration (as defined below) for each series of Notes. Title of Security CUSIP Number(1) Principal Amount Outstanding U.S. Treasury Reference Security Bloomberg Reference Page Reference Yield Fixed Spread Early Tender Payment (3)(4) Total Consideration(3)(4) 2.600% Senior Unsecured Notes due 2026 071813BQ1 $750,000,000 UST 1.500% due Aug. 15, 2026 FIT3 3.713% +30 bps $30
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)